Abstract
Therapeutic benefits of alpha1-adrenergic antagonists (A1As), namely, prazosin, terazosin and doxazosin, have begun to emerge in a broad range of psychiatric disorders in clinical trials. A1As have shown promise in the treatment of several psychiatric disorders such as posttraumatic stress disorder (PTSD), alcohol dependence, cocaine dependence, nicotine cessation and dementia-related agitation in both animal and human studies. These, and other chronic psychiatric conditions, may be mediated or precipitated by stressful conditions. A1As beneficial effects in these psychiatric disorders are hypothesized via their unique effects on regulating norepinephrine (NE) and corticotrophin releasing factor (CRF), which are two key mediators of stress in the central nervous system (CNS). Despite increasing use of A1As in psychiatric disorders, there is a lack of comprehensive review. Animal studies have suggested that by regulating NE in stressful conditions, A1As can increase the pre-frontal cortical functioning and decrease amygdalar activity. Similarly, rat studies have shown a direct decrease in cerebrospinal fluid (CSF) expression of CRF in rats treated with prazosin in stressful conditions. Thus, A1As may have potential benefit in the treatment and secondary prevention of stress-mediated or precipitated psychiatric disorders. In addition, another beneficial effect of A1As is known to be on improvement of metabolic parameters such as lipid profile and insulin sensitivity.
Keywords: Alpha1-adrenergic receptor antagonists, doxazosin, prazosin terazosin, PTSD, secondary prevention in psychiatric disorders, stress, substance use disorders.
Current Psychopharmacology
Title:Alpha1-Adrenergic Receptor Antagonists Use in Treatment and Prevention of Psychiatric Disorders: A Review
Volume: 3
Author(s): Abhishek Wadhawan, Alok Banga, Yinghui Duan, Michel Mennesson and Zhao Helen Wu
Affiliation:
Keywords: Alpha1-adrenergic receptor antagonists, doxazosin, prazosin terazosin, PTSD, secondary prevention in psychiatric disorders, stress, substance use disorders.
Abstract: Therapeutic benefits of alpha1-adrenergic antagonists (A1As), namely, prazosin, terazosin and doxazosin, have begun to emerge in a broad range of psychiatric disorders in clinical trials. A1As have shown promise in the treatment of several psychiatric disorders such as posttraumatic stress disorder (PTSD), alcohol dependence, cocaine dependence, nicotine cessation and dementia-related agitation in both animal and human studies. These, and other chronic psychiatric conditions, may be mediated or precipitated by stressful conditions. A1As beneficial effects in these psychiatric disorders are hypothesized via their unique effects on regulating norepinephrine (NE) and corticotrophin releasing factor (CRF), which are two key mediators of stress in the central nervous system (CNS). Despite increasing use of A1As in psychiatric disorders, there is a lack of comprehensive review. Animal studies have suggested that by regulating NE in stressful conditions, A1As can increase the pre-frontal cortical functioning and decrease amygdalar activity. Similarly, rat studies have shown a direct decrease in cerebrospinal fluid (CSF) expression of CRF in rats treated with prazosin in stressful conditions. Thus, A1As may have potential benefit in the treatment and secondary prevention of stress-mediated or precipitated psychiatric disorders. In addition, another beneficial effect of A1As is known to be on improvement of metabolic parameters such as lipid profile and insulin sensitivity.
Export Options
About this article
Cite this article as:
Wadhawan Abhishek, Banga Alok, Duan Yinghui, Mennesson Michel and Helen Wu Zhao, Alpha1-Adrenergic Receptor Antagonists Use in Treatment and Prevention of Psychiatric Disorders: A Review, Current Psychopharmacology 2014; 3 (3) . https://dx.doi.org/10.2174/2211556004666150507220211
DOI https://dx.doi.org/10.2174/2211556004666150507220211 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Risk Factors of Alzheimers Disease Among Iranian Population
Current Alzheimer Research Vasoactive Intestinal Peptide in Neurodevelopmental Disorders:Therapeutic Potential
Current Pharmaceutical Design Neuroprotective Properties of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) and its Lipid Ligands
Current Medicinal Chemistry Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease
Current Alzheimer Research Anti-Inflammatory Agents from Plants: Progress and Potential
Current Medicinal Chemistry Wound Healing Effects of Curcumin: A Short Review
Current Pharmaceutical Biotechnology Lipid-lowering Drug Therapy in Elderly Patients
Current Pharmaceutical Design Pharmacological Management of Acutely Agitated Schizophrenic Patients
Current Pharmaceutical Design subject Index To Volume 1
Current Drug Targets - Inflammation & Allergy Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence
Current Neuropharmacology Insulin Resistance and Alzheimers Disease Pathogenesis: Potential Mechanisms and Implications for Treatment
Current Alzheimer Research Animal Models in Neurology: Drawbacks and Opportunities
Current Pharmaceutical Design Drugs of Abuse-Induced Hyperthermia, Blood-Brain Barrier Dysfunction and Neurotoxicity: Neuroprotective Effects of a New Antioxidant Compound H-290/51
Current Pharmaceutical Design Targeted Nanoparticles for the Treatment of Alzheimer's Disease
Current Pharmaceutical Design Assessing Medication Problems in those ≥ 65 Using the STOPP and START Criteria
Current Aging Science Neovascular Age-Related Macular Degeneration and its Association with Alzheimer’s Disease
Current Aging Science Recent Developments in the Understanding and Treatment of Neurodegenerative Disorders Involving Protein Conformational Misfolding and Amyloid Formation
Medicinal Chemistry Reviews - Online (Discontinued) Syntheses of Ethyl Pyruvate’s Bioisosteres Inhibiting Inducible Nitric Oxide Production in Lipopolysaccharide-induced BV2 Cells
Letters in Drug Design & Discovery Relationship Between Cigarette Smoking and Other Coronary Risk Factors in Atherosclerosis: Risk of Cardiovascular Disease and Preventive Measures
Current Pharmaceutical Design Ubiquitin Enzymes, Ubiquitin and Proteasome Activity in Blood Mononuclear Cells of MCI, Alzheimer and Parkinson Patients
Current Alzheimer Research